Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Consensus Rating of “Buy” from Brokerages

Cellebrite DI Ltd. (NASDAQ:CLBT) has been given an average rating of “Buy” by the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $18.57.

A number of equities analysts have recently issued reports on the company. Craig Hallum increased their price target on Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Needham & Company LLC increased their price target on Cellebrite DI from $14.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. TD Cowen increased their price target on Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Deutsche Bank Aktiengesellschaft increased their price target on Cellebrite DI from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Finally, Bank of America increased their price target on Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, August 16th.

Cellebrite DI Stock Down 0.8 %

CLBT stock opened at $16.55 on Friday. The business’s fifty day simple moving average is $15.87 and its two-hundred day simple moving average is $12.99. Cellebrite DI has a twelve month low of $6.36 and a twelve month high of $17.82. The firm has a market cap of $3.41 billion, a price-to-earnings ratio of -28.53, a PEG ratio of 2.32 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Thursday, August 15th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. Cellebrite DI had a positive return on equity of 5,902.06% and a negative net margin of 28.51%. The business had revenue of $95.70 million for the quarter, compared to analyst estimates of $91.94 million. During the same quarter last year, the firm posted $0.05 earnings per share. The business’s revenue was up 24.8% compared to the same quarter last year. Research analysts expect that Cellebrite DI will post 0.31 EPS for the current year.

Institutional Investors Weigh In On Cellebrite DI

Institutional investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC boosted its position in Cellebrite DI by 75.0% during the fourth quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock valued at $30,000 after purchasing an additional 1,500 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its holdings in Cellebrite DI by 59.6% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock worth $33,000 after acquiring an additional 1,017 shares in the last quarter. Quarry LP acquired a new stake in Cellebrite DI in the fourth quarter worth about $36,000. Public Employees Retirement Association of Colorado acquired a new stake in Cellebrite DI in the second quarter worth about $71,000. Finally, nVerses Capital LLC acquired a new stake in Cellebrite DI in the second quarter worth about $103,000. Institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.